New re­search ar­gues drug pric­ing ne­go­ti­a­tions would stymie in­no­va­tion, as De­moc­rats fight for re­vised pro­pos­al

As De­moc­rats ham­mer out a re­vised ver­sion of their pro­pos­al to low­er drug prices, new re­search from the Uni­ver­si­ty of Chica­go sug­gests that Medicare ne­go­ti­a­tions could stymie the de­vel­op­ment of new can­cer drugs — but the size of that ef­fect is wide­ly de­bat­ed.

Can­cer treat­ments ac­count­ed for about 49% of the pipeline mak­ing its way through the FDA now, and 27% of new ap­provals be­tween 2010 and 2019, ac­cord­ing to the UC analy­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.